NI201100105A - Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y melfalan. - Google Patents
Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y melfalan.Info
- Publication number
- NI201100105A NI201100105A NI201100105A NI201100105A NI201100105A NI 201100105 A NI201100105 A NI 201100105A NI 201100105 A NI201100105 A NI 201100105A NI 201100105 A NI201100105 A NI 201100105A NI 201100105 A NI201100105 A NI 201100105A
- Authority
- NI
- Nicaragua
- Prior art keywords
- melfalan
- specifically recognize
- containing antibodies
- combinations containing
- tumor
- Prior art date
Links
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 title abstract 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 title abstract 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 title abstract 2
- 229960001924 melphalan Drugs 0.000 title abstract 2
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composición farmacéutica que comprende un anticuerpo que reconoce específicamente la CD38 y melfalan.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08291116A EP2191840A1 (en) | 2008-11-28 | 2008-11-28 | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
Publications (1)
Publication Number | Publication Date |
---|---|
NI201100105A true NI201100105A (es) | 2011-12-13 |
Family
ID=40578382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI201100105A NI201100105A (es) | 2008-11-28 | 2011-05-27 | Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y melfalan. |
Country Status (33)
Country | Link |
---|---|
US (1) | US9259406B2 (es) |
EP (2) | EP2191840A1 (es) |
JP (3) | JP2012510461A (es) |
KR (1) | KR101733252B1 (es) |
CN (1) | CN102264385B (es) |
AR (1) | AR074219A1 (es) |
AU (1) | AU2009321249B2 (es) |
BR (1) | BRPI0921864B1 (es) |
CA (1) | CA2744990C (es) |
CL (1) | CL2011001254A1 (es) |
CO (1) | CO6440557A2 (es) |
CR (1) | CR20110280A (es) |
EA (1) | EA026867B1 (es) |
EC (1) | ECSP11011062A (es) |
HK (1) | HK1164165A1 (es) |
HN (1) | HN2011001417A (es) |
IL (1) | IL213116B (es) |
MA (1) | MA32896B1 (es) |
ME (1) | ME01136B (es) |
MX (1) | MX342625B (es) |
MY (1) | MY164577A (es) |
NI (1) | NI201100105A (es) |
NZ (1) | NZ593027A (es) |
PA (1) | PA8850101A1 (es) |
PE (1) | PE20120340A1 (es) |
SG (1) | SG171820A1 (es) |
SV (1) | SV2011003924A (es) |
TN (1) | TN2011000232A1 (es) |
TW (1) | TWI454260B (es) |
UA (1) | UA107069C2 (es) |
UY (1) | UY32263A (es) |
WO (1) | WO2010061357A1 (es) |
ZA (1) | ZA201103925B (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
CA3122219A1 (en) | 2010-04-16 | 2011-10-20 | The Children's Hospital Corporation | Sustained polypeptide expression from synthetic, modified rnas and uses thereof |
WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
SG188345A1 (en) | 2010-09-27 | 2013-04-30 | Morphosys Ag | Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl |
CA2821992A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
UA112170C2 (uk) * | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
ES2911677T3 (es) | 2011-10-03 | 2022-05-20 | Modernatx Inc | Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos |
DE12858350T1 (de) | 2011-12-16 | 2021-10-07 | Modernatx, Inc. | Modifizierte mrna zusammensetzungen |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
EP3501550A1 (en) | 2012-04-02 | 2019-06-26 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
WO2014048921A1 (en) | 2012-09-25 | 2014-04-03 | Morphosys Ag | Combinations and uses thereof |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
UA118255C2 (uk) * | 2012-12-07 | 2018-12-26 | Санофі | Композиція, яка містить антитіло до cd38 і леналідомід |
US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
MA44560B2 (fr) | 2014-07-31 | 2021-01-29 | Sanofi Sa | Anticorps anti-cd38 spécifiques pour le traitement de cancers humains |
WO2016022589A2 (en) | 2014-08-08 | 2016-02-11 | The Regents Of The University Of California | Methods for treating multiple myeloma |
JP6707531B2 (ja) | 2014-09-09 | 2020-06-10 | ヤンセン バイオテツク,インコーポレーテツド | 抗cd38抗体による併用療法 |
MX2017007208A (es) | 2014-12-04 | 2018-01-30 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de leucemia mieloide aguda. |
CR20170526A (es) | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
EP3310386B1 (en) | 2015-06-22 | 2021-07-21 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
LT3827845T (lt) | 2015-11-03 | 2022-06-10 | Janssen Biotech, Inc. | Poodinės anti-cd38 antikūnų kompozicijos ir jų naudojimas |
US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
WO2019089832A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
US20210145778A1 (en) * | 2018-01-01 | 2021-05-20 | Orbicular Pharmaceutical Technologies Pvt. Ltd. | Stable Liquid Compositions of Melphalan |
WO2020187718A1 (en) | 2019-03-15 | 2020-09-24 | Morphosys Ag | Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease |
US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
MX2022006882A (es) | 2019-12-05 | 2022-11-08 | Sanofi Aventis Us Llc | Formulaciones de anticuerpos anti-cd38 para administracion subcutanea. |
US20240109977A1 (en) | 2021-01-14 | 2024-04-04 | Morphosys Ag | Anti-cd38 antibodies and their uses |
TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗cd38抗體 |
TW202321303A (zh) | 2021-07-19 | 2023-06-01 | 德商莫菲西斯公司 | 抗pla2r自體抗體媒介膜性腎病變之治療 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB750155A (en) | 1953-03-17 | 1956-06-13 | Nat Res Dev | Substituted alanines |
US3032585A (en) | 1954-12-03 | 1962-05-01 | Nat Res Dev | Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine |
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
EP0970126B1 (en) | 1997-04-14 | 2001-04-18 | Micromet AG | Novel method for the production of antihuman antigen receptors and uses thereof |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
CA2329940A1 (en) * | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
GB0221574D0 (en) | 2002-09-17 | 2002-10-23 | Isis Innovation | Treatments |
EP2511297B1 (en) | 2004-02-06 | 2015-04-08 | MorphoSys AG | Anti-CD38 human antibodies and uses therefor |
US7829673B2 (en) * | 2005-03-23 | 2010-11-09 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
SI2081595T1 (sl) | 2006-09-26 | 2019-10-30 | Genmab As | Anti-cd38 plus kortikosteroidi plus ne-kortikosteroidni kemoterapevtik za zdravljenje tumorjev |
US20080092384A1 (en) * | 2006-10-16 | 2008-04-24 | Schaake Mark D | Installation of Middle Bearing for a Crankshaft |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
-
2008
- 2008-11-28 EP EP08291116A patent/EP2191840A1/en not_active Ceased
-
2009
- 2009-11-25 PA PA20098850101A patent/PA8850101A1/es unknown
- 2009-11-25 TW TW098140158A patent/TWI454260B/zh active
- 2009-11-25 AR ARP090104545A patent/AR074219A1/es not_active Application Discontinuation
- 2009-11-25 UY UY0001032263A patent/UY32263A/es not_active Application Discontinuation
- 2009-11-27 CA CA2744990A patent/CA2744990C/en not_active Expired - Fee Related
- 2009-11-27 AU AU2009321249A patent/AU2009321249B2/en active Active
- 2009-11-27 KR KR1020117014746A patent/KR101733252B1/ko active IP Right Grant
- 2009-11-27 ME MEP-2011-93A patent/ME01136B/me unknown
- 2009-11-27 CN CN200980148094.4A patent/CN102264385B/zh active Active
- 2009-11-27 MY MYPI2011002367A patent/MY164577A/en unknown
- 2009-11-27 EP EP09775302A patent/EP2370094A1/en not_active Withdrawn
- 2009-11-27 NZ NZ593027A patent/NZ593027A/xx unknown
- 2009-11-27 UA UAA201108006A patent/UA107069C2/uk unknown
- 2009-11-27 PE PE2011001107A patent/PE20120340A1/es active IP Right Grant
- 2009-11-27 MX MX2011005670A patent/MX342625B/es active IP Right Grant
- 2009-11-27 US US13/130,862 patent/US9259406B2/en active Active
- 2009-11-27 SG SG2011037967A patent/SG171820A1/en unknown
- 2009-11-27 JP JP2011538092A patent/JP2012510461A/ja not_active Withdrawn
- 2009-11-27 WO PCT/IB2009/055389 patent/WO2010061357A1/en active Application Filing
- 2009-11-27 BR BRPI0921864-5A patent/BRPI0921864B1/pt active IP Right Grant
- 2009-11-27 EA EA201100864A patent/EA026867B1/ru not_active IP Right Cessation
-
2011
- 2011-05-11 TN TN2011000232A patent/TN2011000232A1/fr unknown
- 2011-05-19 EC EC2011011062A patent/ECSP11011062A/es unknown
- 2011-05-24 IL IL213116A patent/IL213116B/en active IP Right Grant
- 2011-05-26 CR CR20110280A patent/CR20110280A/es unknown
- 2011-05-27 NI NI201100105A patent/NI201100105A/es unknown
- 2011-05-27 CO CO11065644A patent/CO6440557A2/es unknown
- 2011-05-27 CL CL2011001254A patent/CL2011001254A1/es unknown
- 2011-05-27 SV SV2011003924A patent/SV2011003924A/es unknown
- 2011-05-27 ZA ZA2011/03925A patent/ZA201103925B/en unknown
- 2011-05-27 HN HN2011001417A patent/HN2011001417A/es unknown
- 2011-06-13 MA MA33937A patent/MA32896B1/fr unknown
-
2012
- 2012-05-25 HK HK12105154.7A patent/HK1164165A1/xx unknown
-
2015
- 2015-05-27 JP JP2015107404A patent/JP6148696B2/ja active Active
-
2017
- 2017-03-01 JP JP2017037860A patent/JP2017141233A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201100105A (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y melfalan. | |
NI201100104A (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y ciclofosfamida. | |
NI201100107A (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente la cd38 y la citarabina. | |
NI201100106A (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y vincristina. | |
NI201300050A (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y bortezomib. |